Testosterone

2022 - 11 - 2

Post cover — Image courtesy of "ESG Clarity"

'Testosterone effect' in investing scuppers long-term climate goals ... (ESG Clarity)

Thought leader Sandrine Dixson-Declève says robust EU green taxonomy could have transformed financial system.

[Covid-19](https://esgclarity.com/is-there-a-covid-19-esg-test-for-company-behaviour-during-the-crisis/), in particular, there is a real understanding that we need to better foster in our financial system the shift of capital into the parts of our economy that have really been left to the side like… But there are lessons to be taken from the project, according to Dixson-Declève. “It was trying to bring in a much more ambitious set of criteria for climate, environment and social. It would have then been able to be fed much more into the ESG in terms of… However, she expressed concerns “they will not be as ambitious as they should have been”. And that’s that is the difficulty. [transitionary](https://esgclarity.com/fast-and-unfair-energy-transition-will-fail/). The paper argued we would overshoot Earth’s carrying capacity within 100 years if we continued with the growth trends in population, industrialisation and resource use that could be seen then. [science](https://esgclarity.com/scientists-need-place-at-sustainable-finance-table/). Dixson-Declève described issues with financial systems more broadly: “The financial systems no longer reflect people’s needs. [profits](https://esgclarity.com/eu-to-force-fossil-fuel-companies-to-share-profits/). [inequality](https://esgclarity.com/esg-clarity-teams-up-with-reboot-to-tackle-racial-inequality-in-the-workplace/).”

Men's health rethink? Low testosterone levels change depending on ... (Study Finds)

The study suggests the "one-size-fits-all" approach does not work for men in their mid-40s or younger.

[The Journal of Urology](https://www.auajournals.org/doi/10.1097/JU.0000000000002928#:~:text=Age%2Dspecific%20cutoffs%20for%20low%20testosterone%20levels%E2%80%94representing%20the%2033rd,Table%203%20and%20Figure%202.). [engaging in hormone therapy](https://studyfinds.org/testosterone-supplements-covid/) or those with a history of testicular cancer or testicular removal. The cutoff was 350 ng/dL for men between 40 and 44. [testosterone deficiency](https://studyfinds.org/study-finds-a-low-fat-diet-may-lower-testosterone-levels-in-men/). In men between 20 to 24, the cutoff for low testosterone was 409 ng/dL. This could contribute to a [low sex drive](https://studyfinds.org/vegetarian-lower-testosterone-men/) and erectile dysfunction.

Is it time to revise standard cut off of 300 ng/dL for testosterone ... (Medical Dialogues)

USA: A recent study in the Journal of Urology has suggested that age-specific testosterone cutoffs and reference ranges should be used for evaluating ...

Rethinking the 300 ng/dL Cutoff for Testosterone Deficiency in Men 20-44 Years Old. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. Men were separated into 5-year intervals, and the researchers investigated the testosterone levels of each group for all men aged 20 to 44. Therefore, it is surprising that young men are investigated for testosterone deficiency with a similar cutoff of 300 ng/dL developed from samples of older men. Men aged 20 to 44 years with testosterone levels were included. "However, young and older men have different testosterone reference ranges."

Grünenthal closes deal to acquire testosterone therapy Nebido ... (PRNewswire)

PRNewswire/ -- Grünenthal today announced the successful completion of its acquisition of NebidoTM from Bayer for €495 million. "Testosterone deficiency...

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America and the US. NebidoTM is the only available injectable long-acting depot preparation of testosterone undecanoate, developed for the treatment of male hypogonadism. NebidoTM is the leading brand for the treatment of male hypogonadism. In 2021, Grünenthal employed around 4,500 people and achieved sales of € 1.5 bn. As of closing, Grünenthal will immediately take over commercialisation and supply for the majority of European and Latin American markets. Grünenthal has invested over €2 billion in successful M&A transactions over the past years. As a science-based, fully-integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. We are focusing all of our activities and efforts on working towards our vision of a world free of pain. The Journal of Clinical Endocrinology & Metabolism, 92(11), 4241-4247. The acquisition of Nebido™ is part of a series of acquisitions by Grünenthal, including the European rights to CRESTOR™ and Nexium™, the global rights to Vimovo™ (ex-US and Japan), the global rights to Qutenza™ and the global rights to Zomig™ (ex-Japan). "Testosterone deficiency affects one in six men over 50 years1; representing a significant burden," said Gabriel Baertschi, CEO Grünenthal. For Grünenthal, the acquisition is the second largest in the company's history.

Grünenthal closes deal to acquire testosterone therapy Nebido ... (Yahoo Finance)

Grünenthal today announced the successful completion of its acquisition of NebidoTM from Bayer for €495 million.